Oral Typhoid Vaccine Market to Hit USD 363.95 Million by 2032

Posted 2026-02-12 05:59:06

“According to a new report published by Introspective Market Research, Oral Typhoid Vaccine Market by Type, Distribution Channel, and End User, the Global Oral Typhoid Vaccine Market Size Was Valued at USD 127.10 Million in 2023 and is Projected to Reach USD 363.95 Million by 2032, Growing at a CAGR of 12.40% from 2024 to 2032.”

The oral typhoid vaccine market plays a critical role in preventing typhoid fever, a life-threatening bacterial infection caused by Salmonella typhi, particularly prevalent in developing and underdeveloped regions. Oral typhoid vaccines offer several advantages over injectable alternatives, including ease of administration, better patient compliance, and suitability for mass immunization programs. These vaccines are widely used in routine immunization schedules, outbreak control initiatives, and travel vaccination programs.

Rising awareness of typhoid prevention, increasing government-led vaccination campaigns, and support from global health organizations such as WHO and UNICEF are driving market expansion. Oral vaccines are especially beneficial in pediatric populations and resource-limited settings, where cold-chain logistics and trained healthcare professionals may be constrained.

Furthermore, advancements in vaccine formulation, growing investments in public health infrastructure, and increased focus on preventive healthcare are expected to significantly support market growth during the forecast period.

Market Segmentation

The Oral Typhoid Vaccine Market is segmented into Type, Distribution Channel, and End User.
By Type, the market is categorized into (Live Attenuated Vaccines, Combination Vaccines).
By Distribution Channel, the market is categorized into (Public Health Programs, Private Healthcare Providers).
By End User, the market is categorized into (Hospitals & Clinics, Pediatric Centers, Travel Clinics).

Growth Driver

The primary growth driver of the oral typhoid vaccine market is the increasing prevalence of typhoid fever in low- and middle-income countries. Poor sanitation, lack of clean drinking water, and rapid urbanization have heightened disease transmission risks. Governments and international organizations are prioritizing preventive vaccination programs to reduce disease burden and mortality rates. Oral vaccines, with their ease of administration and cost-effectiveness, are increasingly favored for large-scale immunization campaigns, thereby significantly accelerating market growth.

Market Opportunity

A key opportunity in the oral typhoid vaccine market lies in expanding immunization coverage across emerging economies. Increased funding from global health agencies, coupled with national vaccination initiatives, is opening new avenues for manufacturers. Additionally, rising travel to typhoid-endemic regions has increased demand for oral typhoid vaccines among travelers. Technological advancements in vaccine stability and shelf life further present lucrative opportunities for market players to expand their geographic reach.

Detailed Segmentation

Oral Typhoid Vaccine Market, Segmentation

The Oral Typhoid Vaccine Market is segmented on the basis of Type, Distribution Channel, and End User.

Type

The Type segment is further classified into Live Attenuated Vaccines and Combination Vaccines. Among these, the Live Attenuated Vaccines sub-segment accounted for the highest market share in 2023. This dominance is attributed to their proven efficacy, long-lasting immunity, and widespread adoption in public immunization programs. These vaccines are easy to administer orally and are particularly effective in pediatric populations, making them the preferred choice for mass vaccination initiatives globally.

Distribution Channel

The Distribution Channel segment is further classified into Public Health Programs and Private Healthcare Providers. Among these, the Public Health Programs sub-segment held the highest market share in 2023. Government-supported vaccination drives, international funding support, and inclusion of oral typhoid vaccines in national immunization schedules have significantly contributed to this segment’s leadership, especially in typhoid-endemic regions.

Some of The Leading/Active Market Players Are

• Bharat Biotech (India)
• PaxVax Inc. (USA)
• Sanofi (France)
• Emergent BioSolutions (USA)
• GlaxoSmithKline plc (UK)
• Biological E Limited (India)
• Serum Institute of India Pvt. Ltd. (India)
• PT Bio Farma (Indonesia)
• VBI Vaccines Inc. (USA)
• Mitsubishi Tanabe Pharma (Japan)
• AstraZeneca plc (UK)
• Valneva SE (France)
• Takeda Pharmaceutical Company (Japan)
• Pfizer Inc. (USA)
• CSL Limited (Australia)
and other active players.

Key Industry Developments

In March 2024, a leading vaccine manufacturer announced expanded production capacity for oral typhoid vaccines to support global immunization initiatives.
This expansion aims to meet growing demand from developing countries and international health agencies, ensuring improved access to affordable vaccines and supporting disease eradication efforts.

In October 2023, a public-private partnership was formed to enhance oral typhoid vaccine distribution in high-burden regions.
The collaboration focuses on strengthening supply chains, improving vaccine accessibility, and increasing awareness through community-based immunization programs.

Key Findings of the Study

• Live attenuated vaccines dominated the market in 2023
• Public health programs remain the leading distribution channel
• Asia-Pacific emerged as the fastest-growing region
• Rising typhoid prevalence is the key growth driver
• Preventive healthcare trends support long-term market expansion

More Info:- https://introspectivemarketresearch.com/reports/oral-typhoid-vaccine-market/

About Us

At Introspective Market Research Private Limited, we are a forward-thinking research consulting firm committed to driving growth in the Oral Typhoid Vaccine Market. With deep insights, strategic solutions, and holistic research, we empower businesses to achieve success and dominance in the global vaccine industry.